Adze oncolytic immunotherapies harness immune response mechanisms to enable the patient's body to fight cancers.
Adze oncolytic immunotherapy payloads target immune stimulatory and inhibitory receptors on T, NK, and dendritic cells and macrophages to further amplify the immune response.
The neoantigens released from lysed cancer cells, coupled with recruited and stimulated immune cells, generate in situ systemic cancer vaccine responses, a key goal in immuno-oncology.
Our virotherapy platform targets the same immune checkpoints as current therapies, but also kills cancer cells and exposes cancer antigens to the immune system.
Proprietary modifications to our viral particles help escape circulating macrophages for improved potency.
Copyright © 2021 Adze Biotechnology - All Rights Reserved.